NRAS and melanoma: These results align with data from the The Cancer Genome Atlas (TCGA) study, which reported BRAF mutations in approximately 50% of melanoma cases, NRAS mutations in 30%, NF1 mutations in 12–23%, and PTEN mutations in 5–40% of cases (22, 26).